Why Lasmiditan?
Lasmiditan is a member of a novel chemical class called "ditans".
Lasmiditan penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway.
Learn More About Lasmiditan
Lasmiditan has a unique pyridinoyl-piperidine chemical scaffold and is completely different from triptans, which act peripherally by constricting blood vessels and do not penetrate the CNS.
* Lasmiditan is for investigational use only
Lasmiditan does not interact with vasoconstrictor 5-HT1B/1D receptors activated by triptans.
No evidence of drug-related cardiovascular adverse effects or chest symptoms in the previous six clinical studies.
Learn More About Lasmiditan
Phase 3 studies to confirm that side effect profile is highly differentiated from triptans and ergotamines.
* Lasmiditan is for investigational use only
Six clinical studies provide proof of concept in the treatment of acute migraine attacks.
Reduced moderate or severe headache at baseline to mild or none 2 hours after dosing (p<0.0001) in 391 patients.
Differentiation of individual doses from placebo seen as early as 30 minutes after dosing.
Learn More About Lasmiditan
Provided relief of nausea, photophobia (sensitivity to light) and phonophobia. (sensitivity to sound).
* Lasmiditan is for investigational use only
